Dynavax Technologies (NASDAQ:DVAX) Cut to C+ at TheStreet

Dynavax Technologies Co.  logoTheStreet cut shares of Dynavax Technologies (NASDAQ:DVAX – Get Rating) from a b- rating to a c+ rating in a report released on Thursday morning, TheStreetRatingsTable reports.

Separately, StockNews.com upgraded Dynavax Technologies from a hold rating to a buy rating in a report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $28.00.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $11.21 on Thursday. The stock’s 50-day moving average is $13.86 and its 200-day moving average is $11.89. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 8.01 and a beta of 1.30. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.77 and a quick ratio of 2.55. Dynavax Technologies has a 12 month low of $7.26 and a 12 month high of $21.39.

Insider Activity at Dynavax Technologies

Want More Great Investing Ideas?

In related news, SVP Robert Janssen sold 7,938 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $16.92, for a total transaction of $134,310.96. Following the sale, the senior vice president now directly owns 35,519 shares in the company, valued at approximately $600,981.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Dynavax Technologies news, COO David F. Novack sold 26,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $16.92, for a total transaction of $444.150.00. Following the completion of the sale, the chief operating officer now owns 53,213 shares in the company, valued at approximately $900,363.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Robert Janssen sold 7,938 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $16.92, for a total value of $134,310.96. Following the sale, the senior vice president now owns 35,519 shares of the company’s stock, valued at approximately $600,981.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,109 shares of company stock worth $1,088,474. 9.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DVAX. American Century Companies Inc. grew its position in shares of Dynavax Technologies by 54.7% in the 4th quarter. American Century Companies Inc. now owns 82,990 shares of the biopharmaceutical company’s stock worth $1,168,000 after acquiring an additional 29,344 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Dynavax Technologies by 70.6% in the 4th quarter. ProShare Advisors LLC now owns 23,556 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 9,747 shares in the last quarter. Raymond James & Associates acquired a new position in shares of Dynavax Technologies in the 4th quarter worth approximately $153,000. Bank of America Corp DE grew its position in shares of Dynavax Technologies by 356.1% in the 4th quarter. Bank of America Corp DE now owns 322,762 shares of the biopharmaceutical company’s stock worth $4,541,000 after acquiring an additional 251,995 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Dynavax Technologies in the 4th quarter worth approximately $721,000. Institutional investors and hedge funds own 96.66% of the company’s stock.

Dynavax Technologies Company Profile

(Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Stories

Receive News & Ratings for Dynavax Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dynavax Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *